Drug Approval | July 11, 2023
NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
Approval to dramatically change CAR-T therapies landscape
Approval to dramatically change CAR-T therapies landscape
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Furthering cell therapy ambition across oncology and autoimmune diseases
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Subscribe To Our Newsletter & Stay Updated
